These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32667708)

  • 1. pH and excipient profiles during formulation of highly concentrated biotherapeutics using bufferless media.
    Jabra MG; Tao Y; Moomaw JF; Yu Z; Hotovec BJ; Geng SB; Zydney AL
    Biotechnol Bioeng; 2020 Nov; 117(11):3390-3399. PubMed ID: 32667708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass Balance Model with Donnan Equilibrium Accurately Describes Unusual pH and Excipient Profiles during Diafiltration of Monoclonal Antibodies.
    Baek Y; Singh N; Arunkumar A; Borwankar A; Zydney AL
    Biotechnol J; 2019 Jul; 14(7):e1800517. PubMed ID: 30791230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration/diafiltration process of protein formulations.
    Yu Z; Moomaw JF; Thyagarajapuram NR; Geng SB; Bent CJ; Tang Y
    Biotechnol Prog; 2021 Mar; 37(2):e3106. PubMed ID: 33289341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of protein and solution properties on the Donnan effect during the ultrafiltration of proteins.
    Bolton GR; Boesch AW; Basha J; Lacasse DP; Kelley BD; Acharya H
    Biotechnol Prog; 2011; 27(1):140-52. PubMed ID: 21312362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic model of pH and excipient concentration during ultrafiltration and diafiltration processes of therapeutic antibodies.
    Ladwig JE; Zhu X; Rolandi P; Hart R; Robinson J; Rydholm A
    Biotechnol Prog; 2020 Sep; 36(5):e2993. PubMed ID: 32185869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.
    Teeters M; Bezila D; Benner T; Alfonso P; Alred P
    Biotechnol Bioeng; 2011 Jun; 108(6):1338-46. PubMed ID: 21328314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
    Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
    J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Formulation Conditions During Ultrafiltration and Dilution to Drug Substance Using a Donnan Model with Homology-Model Based Protein Charge.
    Kannan A; Chinn M; Izadi S; Maier A; Dvornicky J; Fedesco M; Day E; Ladiwala A; Woys A
    J Pharm Sci; 2023 Mar; 112(3):820-829. PubMed ID: 36336103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations.
    Thakur G; Hebbi V; Rathore AS
    Int J Pharm; 2021 May; 600():120456. PubMed ID: 33711473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH variations during diafiltration due to buffer nonidealities.
    Baek Y; Yang D; Singh N; Arunkumar A; Ghose S; Li ZJ; Zydney AL
    Biotechnol Prog; 2017 Nov; 33(6):1555-1560. PubMed ID: 28840650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
    Miao F; Velayudhan A; DiBella E; Shervin J; Felo M; Teeters M; Alred P
    Biotechnol Prog; 2009; 25(4):964-72. PubMed ID: 19569193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing scalable ultrafiltration/diafiltration process of monoclonal antibodies via mathematical modeling by coupling mass balances and Poisson-Boltzmann equation.
    Ambrožič R; Arzenšek D; Podgornik A
    Biotechnol Bioeng; 2021 Feb; 118(2):633-646. PubMed ID: 33049074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of Electrostatic Mediated Antibody Liquid-Liquid Phase Separation by Charged and Noncharged Preferentially Excluded Excipients.
    Banks DD; Cordia JF
    Mol Pharm; 2021 Mar; 18(3):1285-1292. PubMed ID: 33555888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification of singly PEGylated α-lactalbumin using charged ultrafiltration membranes.
    Ruanjaikaen K; Zydney AL
    Biotechnol Bioeng; 2011 Apr; 108(4):822-9. PubMed ID: 21404256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High performance liquid chromatography (HPLC) based direct and simultaneous estimation of excipients in biopharmaceutical products.
    Hebbi V; Chattopadhyay S; Rathore AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1117():118-126. PubMed ID: 31005704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Charge heterogeneity profiling of monoclonal antibodies using low ionic strength ion-exchange chromatography and well-controlled pH gradients on monolithic columns.
    Talebi M; Nordborg A; Gaspar A; Lacher NA; Wang Q; He XZ; Haddad PR; Hilder EF
    J Chromatogr A; 2013 Nov; 1317():148-54. PubMed ID: 24011724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The osmotic pressure of highly concentrated monoclonal antibody solutions: effect of solution conditions.
    Binabaji E; Rao S; Zydney AL
    Biotechnol Bioeng; 2014 Mar; 111(3):529-36. PubMed ID: 23996891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.
    Yang Y; Velayudhan A; Thornhill NF; Farid SS
    Biotechnol Bioeng; 2017 Sep; 114(9):2043-2056. PubMed ID: 28464235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.